MX2022001032A - Agentes terapeuticos multiespecificos a base en aptameros. - Google Patents
Agentes terapeuticos multiespecificos a base en aptameros.Info
- Publication number
- MX2022001032A MX2022001032A MX2022001032A MX2022001032A MX2022001032A MX 2022001032 A MX2022001032 A MX 2022001032A MX 2022001032 A MX2022001032 A MX 2022001032A MX 2022001032 A MX2022001032 A MX 2022001032A MX 2022001032 A MX2022001032 A MX 2022001032A
- Authority
- MX
- Mexico
- Prior art keywords
- aptamer
- therapeutic agents
- antigen binding
- binding molecules
- multispecific therapeutic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/13—Applications; Uses in screening processes in a process of directed evolution, e.g. SELEX, acquiring a new function
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se proporcionan moléculas de unión a antígeno multiespecíficas diseñadas que contienen dos o más fracciones de aptámero diferentes unidas por un enlazador. Las moléculas de unión a antígeno son capaces de unirse específicamente a uno o más antígenos y unir diferentes tipos de células, tales como células inmunitarias y células cancerosas. Los aptámeros enlazados se pueden utilizar para modular y mejorar la función inmunitaria.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962879413P | 2019-07-26 | 2019-07-26 | |
US201962879401P | 2019-07-26 | 2019-07-26 | |
PCT/IB2019/000890 WO2020021338A2 (en) | 2018-07-26 | 2019-07-26 | Aptamer-based car t-cell switch |
PCT/IB2020/000623 WO2021019297A1 (en) | 2019-07-26 | 2020-07-27 | Aptamer-based multispecific therapeutic agents |
PCT/IB2020/000635 WO2021019301A2 (en) | 2019-07-26 | 2020-07-27 | Anti-cd3 aptamers for use in cell targeting and labeling |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022001032A true MX2022001032A (es) | 2022-05-24 |
Family
ID=74229604
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022001032A MX2022001032A (es) | 2019-07-26 | 2020-07-27 | Agentes terapeuticos multiespecificos a base en aptameros. |
MX2022001033A MX2022001033A (es) | 2019-07-26 | 2020-07-27 | Aptámeros anti-cd3 para uso en direccionamiento y etiquetado de células. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022001033A MX2022001033A (es) | 2019-07-26 | 2020-07-27 | Aptámeros anti-cd3 para uso en direccionamiento y etiquetado de células. |
Country Status (9)
Country | Link |
---|---|
US (2) | US20220403391A1 (es) |
EP (2) | EP4004209A2 (es) |
JP (2) | JP2022542198A (es) |
KR (2) | KR20220083667A (es) |
CN (2) | CN114630908A (es) |
AU (2) | AU2020321673A1 (es) |
CA (2) | CA3148799A1 (es) |
MX (2) | MX2022001032A (es) |
WO (2) | WO2021019297A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111235106B (zh) * | 2019-08-30 | 2022-08-05 | 武汉大学 | 一种靶向肿瘤细胞的Aptamer-CD3+T细胞及其构建方法与应用 |
CN114990122A (zh) * | 2022-05-18 | 2022-09-02 | 清华大学 | 共价抑制剂的体外筛选方法及其应用 |
CN115786349B (zh) * | 2022-08-16 | 2024-02-09 | 湖南大学 | 一种用于外周血中杀伤性t淋巴细胞无痕分选的核酸适体、互补序列及其应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
BRPI0514984A (pt) * | 2004-09-07 | 2008-07-01 | Archemix Corp | aptámeros para o fator de von willebrand e sua utilização como terapêuticos para doença trombótica |
US20130209514A1 (en) * | 2009-06-09 | 2013-08-15 | Eli Gilboa | Aptamer-targeted costimulatory ligand aptamer |
EP2990416B1 (en) | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
US11634704B2 (en) * | 2015-04-13 | 2023-04-25 | Research Foundation Of The City University Of New York | Ligand-guided-selection method for screening antigen-specific ligands |
JOP20160154B1 (ar) * | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
SI3411404T1 (sl) * | 2016-02-03 | 2023-01-31 | Amgen Research (Munich) Gmbh | Konstrukti bispecifičnih protiteles PSMA in CD3, ki aktivirajo T celico |
EP3416690A4 (en) * | 2016-02-19 | 2020-02-19 | City of Hope | SPECIFIC APTAMER |
CN107129988A (zh) * | 2016-02-29 | 2017-09-05 | 广西医科大学 | 一种特异性结合cd3的核酸适配体及其筛选方法和应用 |
US20210292760A1 (en) * | 2018-07-26 | 2021-09-23 | Aratinga.Bio Tnp | Aptamer-Based CAR T-Cell Switch |
-
2020
- 2020-07-27 CN CN202080063164.2A patent/CN114630908A/zh active Pending
- 2020-07-27 CN CN202080063162.3A patent/CN114630907A/zh active Pending
- 2020-07-27 WO PCT/IB2020/000623 patent/WO2021019297A1/en active Search and Examination
- 2020-07-27 AU AU2020321673A patent/AU2020321673A1/en active Pending
- 2020-07-27 EP EP20757659.6A patent/EP4004209A2/en active Pending
- 2020-07-27 WO PCT/IB2020/000635 patent/WO2021019301A2/en unknown
- 2020-07-27 US US17/629,627 patent/US20220403391A1/en active Pending
- 2020-07-27 AU AU2020320420A patent/AU2020320420A1/en active Pending
- 2020-07-27 US US17/629,943 patent/US20220251562A1/en active Pending
- 2020-07-27 JP JP2022531083A patent/JP2022542198A/ja active Pending
- 2020-07-27 CA CA3148799A patent/CA3148799A1/en active Pending
- 2020-07-27 MX MX2022001032A patent/MX2022001032A/es unknown
- 2020-07-27 JP JP2022531084A patent/JP2022544337A/ja active Pending
- 2020-07-27 KR KR1020227006665A patent/KR20220083667A/ko unknown
- 2020-07-27 MX MX2022001033A patent/MX2022001033A/es unknown
- 2020-07-27 KR KR1020227006659A patent/KR20220084272A/ko unknown
- 2020-07-27 CA CA3148792A patent/CA3148792A1/en active Pending
- 2020-07-27 EP EP20757658.8A patent/EP4004208A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2022001033A (es) | 2022-05-24 |
JP2022542198A (ja) | 2022-09-29 |
AU2020321673A1 (en) | 2022-03-17 |
WO2021019297A1 (en) | 2021-02-04 |
WO2021019301A3 (en) | 2021-03-11 |
WO2021019301A2 (en) | 2021-02-04 |
EP4004208A1 (en) | 2022-06-01 |
CN114630908A (zh) | 2022-06-14 |
CN114630907A (zh) | 2022-06-14 |
CA3148792A1 (en) | 2021-02-04 |
JP2022544337A (ja) | 2022-10-17 |
US20220403391A1 (en) | 2022-12-22 |
US20220251562A1 (en) | 2022-08-11 |
AU2020320420A1 (en) | 2022-03-17 |
EP4004209A2 (en) | 2022-06-01 |
CA3148799A1 (en) | 2021-02-04 |
KR20220084272A (ko) | 2022-06-21 |
KR20220083667A (ko) | 2022-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022001032A (es) | Agentes terapeuticos multiespecificos a base en aptameros. | |
GEP20227398B (en) | Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof | |
MX2022003718A (es) | Anticuerpos que se unen a cd39 y sus usos. | |
PH12018501778A1 (en) | Antibodies to tigit | |
PH12018500380A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
NZ737471A (en) | Hydrophilic linkers for conjugation | |
CY1119567T1 (el) | Θεραπευτικα πεπτιδια | |
MY164647A (en) | Cea antibodies | |
MY188355A (en) | Human antibodies to pd-l1 | |
MX2015017485A (es) | Uso de moleculas inhibidoras de semaforina-4d en combinacion con una terapia de modulacion inmune para inhibir crecimiento tumoral y metastasis. | |
NZ701575A (en) | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer | |
MX341578B (es) | Tratamiento de la osteoartritis y del dolor. | |
MX2016003744A (es) | Anticuerpos tem8 y su uso. | |
NZ701573A (en) | Carriers for improved drug delivery | |
NZ701585A (en) | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer | |
EP2560684A4 (en) | FIBRONECTIN TYPE III DOMAIN MULTIMERIC SCAFFOLDS | |
EA201890079A1 (ru) | Клеточная система для направленной доставки активного ингредиента | |
PH12017500406A1 (en) | Novel anti-mfi2 antibodies and methods of use | |
MX2018006249A (es) | Nuevos anticuerpos anti-emr2 y metodos de uso. | |
MX2021002144A (es) | Anticuerpo igf-1r y su uso como un vehiculo con especificidad de objetivo para el tratamiento contra el cancer. | |
MX2022001942A (es) | Moléculas de union a antígeno multiespecíficas para el direcciónamiento célular y usos de las mismas. | |
PH12018500159A1 (en) | Constructs targeting psa peptide/mhc complexes and uses thereof | |
MX2022000242A (es) | Anticuerpos contra ticagrelor y metodos de uso. | |
PH12019550194A1 (en) | Anti-ceacam1 antibody and use thereof | |
MX2018007817A (es) | Nuevos anticuerpos anti-mmp16 y metodos para su uso. |